Genus plc

Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.

Genus plc trades as GNS.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £672.80M of revenue and £19.30M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Genus plc can be compared against peers such as Avacta Group Plc, Bioventix PLC, Craneware plc, Faron Pharmaceuticals Oy, HUTCHMED (China) Limited, Oxford Nanopore Technologies plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £1.38B, beta of 0.90, and return on equity of +4.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

GNS.L currently shows total debt of £265.90M and beta of 0.90. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.genusplc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.